Axilum Robotics' Board of Directors is led by Michel Berg. Members are
Arnaud Butzbach, Matthieu Coutet, Romuald Ginhoux, Jacques Lewiner and Pascal Neuville.
Arnaud Butzbach is Co-Founder, Vice-President Operations and Chief Technology Officer at
MEDIAN Technologies, a company listed since 2011 (ALMDT), providing medical imaging
software and services for detection, diagnosis and monitoring of cancers.
From 15 years' experience in the medical imaging industry, surgical robotics
(HealthCenter / Focus imaging, Focus Medical, Deemed…) and in the automotive
industry (Siemens VDO Automotive), Arnaud contributed to all phases of MEDIAN’s
development and brings his experience, expertise and skills in medical imaging,
software engineering, technology transfer and strategic partnerships, to
innovative projects aiming at improving standards of care around the world.
Arnaud Butzbach is graduated from National Polytechnic Institute of Grenoble (INPG)
and Computer sciences and applied mathematics (ENSIMAG).
Matthieu Coutet has been a managing partner with Inserm Transfert Initiative since January 2012.
Graduated from Institut Supérieur de Technologie et de Management in Paris, France, Matthieu joined Inserm
Transfert Initiative in 2005, where he progressively managed the investments and their follow up: He has piloted the
launch and funding of many start-ups like CellVir, Eyevensis, Hemarina and DNA Therapeutics. He is a member
of the board of Sensorion, Eyevensys, Neurokin and Hemarina. Matthieu has managed many company cessions,
particularly Cellvir to Pharmaomnium, Innate Pharma and Immupharma.
Jacques Lewiner is a scientist and an inventor. As a Scientific Director of ESPCI ParisTech in Paris, France,
he worked with Pierre-Gilles de Gennes and created or contributed to the creation of numerous start-ups derived from research.
Some of these start-ups have grown or are expanding rapidly. Jacques Lewiner was awarded the 2010 Prix de l'Ingénieur de l'année
(Engineer of the Year Price) for his life’s work, by the French magazine Usine Nouvelle.
Pascal Neuville is CEO of Domain Therapeutics. He owns a PhD in molecular biology from the University de Strasbourg, France.
He spent five years at the University of Geneva, Switzerland, as a post doc and then as an Assistant Professor.
Then Pascal joined Transgene where he was R&D project leader. From 2002 to 2008, he was CSO of Faust Pharmaceuticals,
a drug discovery and development company in CNS. Pascal Neuville is a board member of Alsace BioValley, the life science
competitiveness cluster of Alsace, France.